Grifols SA (GRFS)
NASDAQ:GRFS
Want to see GRFS full AI Analyst Report?
GRFS Stock Chart & Stats
$8.78
-$0.21(-2.68%)
At close: 4:00 PM EST
$8.78
-$0.21(-2.68%)
Day’s Range― - ―
52-Week Range$7.08 - $11.14
Previous CloseN/A
Volume119.87K
Average Volume (3M)737.71K
Market Cap
$6.55B
Enterprise Value$15.01B
Total Cash (Recent Filing)$824.65M
Total Debt (Recent Filing)$8.74B
Price to Earnings (P/E)14.0
Beta0.99
Next Earnings
May 07, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend Yield1.56%
Share Statistics
EPS (TTM)0.59
Shares Outstanding261,425,100
10 Day Avg. Volume575,743
30 Day Avg. Volume737,714
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.03
Price to Sales (P/S)0.75
P/FCF Ratio7.21
Enterprise Value/Market Cap2.29
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit5.21
Enterprise Value/Ebitda9.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.01
Revenue Forecast (FY)$9.03B
Bulls Say, Bears Say
Bulls Say
Vertical Integration / Plasma SupplyOwning donation centers and internal fractionation creates a durable competitive advantage by securing raw-material supply, reducing procurement risk, and enabling scale economics. This integration supports consistent production volumes and long-term reliability for plasma-derived therapy supply chains.
Improving Cash GenerationSustained positive free cash flow provides structural capacity to pay down debt, fund product launches and manufacturing investment, and support refinancing. Robust cash generation improves financial flexibility over the medium term and underpins deleveraging and strategic options.
Regulatory Wins & Product Portfolio ExpansionNew fibrinogen approvals and launches broaden Grifols' high-value product mix and enable U.S. rollout, diversifying revenue beyond legacy fractions. Combined with solid 2025 top-line growth, these structural product gains should support longer-term market positioning and addressable-market expansion.
Bears Say
High LeverageElevated funded debt materially restricts strategic flexibility, increases refinancing and interest exposure, and limits capacity for large organic or inorganic investments. Even with recent reductions, persistent high leverage is a lasting balance-sheet risk that affects credit metrics and strategic optionality.
Weakened Revenue MomentumA recent top-line pullback interrupts the recovery trend and makes sustained deleveraging and margin recovery more challenging. Continued dependence on specific product categories and geographic demand trends raises medium-term execution risk if growth drivers underperform.
Thin Net Margins / Margin PressureAlthough profitability improved, net margins remain below earlier norms and are sensitive to pricing pressure (notably albumin in China) and below-the-line items. Structural margin compression could limit free cash flow expansion and slow equity rebuilding despite operational gains.
Grifols SA News
GRFS FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $7.08 and its highest was $11.14 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is $6.55B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is May 07, 2026 which is in 2 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on Feb 26, 2026. The company reported $0.168 earnings per share for the quarter, missing the consensus estimate of $0.296 by -$0.128.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA pays a Annually dividend of $0.142 which represents an annual dividend yield of 1.56%. See more information on Grifols SA dividends here
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate is 0.16.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of $0.168 in its last earnings report, missing expectations of $0.296. Following the earnings report the stock price went down -3.135%.
Which hedge fund is a major shareholder of Grifols SA?
Currently, no hedge funds are holding shares in GRFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GRFS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.25%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
4.63%
Trailing 12-Months
Company Description
Grifols SA
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
GRFS Company Deck
GRFS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights Grifols' robust financial performance, with significant revenue growth, improved adjusted EBITDA, and strengthened free cash flow. The company has made progress in deleveraging and gaining market share, particularly in the immunoglobulins franchise. However, challenges such as pricing pressures in China and exchange rate headwinds persist, along with a delay in regulatory approval for fibrinogen in the U.S. Despite these challenges, the overall sentiment leans towards positive, given the strong financial and operational metrics.View all GRFS earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.78% Mutual Funds
0.44% Other Institutional Investors
89.59% Public Companies and
Individual Investors